10X Genomics (NASDAQ:TXG) Surges 13% on Q3 Revenue Beat and Strong Guidance

10X GENOMICS INC-CLASS A (NASDAQ:TXG) delivered a mixed financial performance for the third quarter of 2025, with investors ultimately rewarding the company's stronger-than-expected revenue and optimistic forward guidance despite a year-over-year sales decline. The market reaction was decisively positive, with shares climbing over 13% in after-hours trading following the announcement. This surge indicates that investors are focusing on the company's ability to exceed immediate expectations and its promising outlook for the coming quarter.

Third Quarter Financial Results

The company's Q3 2025 results presented a complex picture, featuring both a revenue beat and a contraction in sales compared to the same period last year. The key financial figures from the quarter are as follows:

• Reported Revenue: $149.0 million
• Analyst Revenue Estimate: Approximately $143.9 million
• Year-over-Year Revenue Change: A decrease of 1.7%
• Reported Non-GAAP EPS: A loss of $0.22 per share
• Analyst EPS Estimate: A loss of $0.29 per share

While the 1.7% drop in sales compared to Q3 2024 will be a point of scrutiny, the company comfortably surpassed Wall Street's forecasts for the quarter. The revenue beat of roughly $5 million and a significantly smaller per-share loss than anticipated were the primary drivers of positive investor sentiment. The smaller-than-expected loss suggests progress in managing operational costs, even as the top line faced slight pressure.

Market Reaction and Price Action

The financial markets responded with notable enthusiasm to the earnings report. The immediate double-digit percentage gain in after-hours trading reflects a consensus that the positives in the report—namely the earnings and revenue beats coupled with strong guidance—outweighed the negative of the year-over-year sales dip. This price action suggests that investors are willing to look past a minor historical setback in favor of the company's current execution and future prospects.

Forward-Looking Guidance

A critical element that fueled the positive market reaction was the company's revenue guidance for the fourth quarter of 2025. Management provided an outlook that surprised analysts with its strength, directly contributing to the stock's upward move.

• Company Q4 Revenue Guidance (Midpoint): $156 million
• Analyst Q4 Revenue Estimate: Approximately $150.7 million

The company's forecast for the next quarter is approximately 3.5% above what analysts had been modeling. This confident outlook signals to the market that management expects a return to growth and strong demand for its single cell and spatial biology platforms in the final quarter of the year.

Press Release Summary

The core announcement from 10x Genomics confirmed the release of its third quarter 2025 financial results. As a leader in the single cell and spatial biology sector, the company highlighted its performance for the period ending September 30, 2025. The press release served as the official channel for disclosing the reported revenue, earnings per share, and the forward guidance that markets have now absorbed.

For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can review the data available on the TXG earnings and estimates page.

---

Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.